共 50 条
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
被引:441
|作者:
Jiang, Ningni
[1
,2
,3
]
Dai, Qijie
[1
,2
,3
]
Su, Xiaorui
[1
,2
,3
]
Fu, Jianjiang
[1
,2
,3
]
Feng, Xuancheng
[1
,2
,3
]
Peng, Juan
[1
,2
,3
,4
]
机构:
[1] Guangzhou Med Univ, Dept Pathol, Affiliated Hosp 3, 63 Duobao Rd, Guangzhou 510150, Peoples R China
[2] Guangzhou Med Univ, Clin Sch 3, Guangzhou 510150, Peoples R China
[3] Guangdong Higher Educ Inst, Key Lab Reprod & Genet, Guangzhou 510150, Peoples R China
[4] Wake Forest Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA
基金:
中国国家自然科学基金;
关键词:
PI3K;
AKT;
PTEN;
Cancer;
Targeted therapy;
EPITHELIAL-MESENCHYMAL TRANSITION;
PROMOTES CELL-PROLIFERATION;
PAPILLARY THYROID-CANCER;
ACUTE MYELOID-LEUKEMIA;
PROTEIN-KINASE B;
RELAPSED/REFRACTORY MULTIPLE-MYELOMA;
AKT INHIBITOR AFURESERTIB;
HUMAN BLADDER-CANCER;
PROSTATE-CANCER;
SIGNALING PATHWAY;
D O I:
10.1007/s11033-020-05435-1
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
Given that the PI3K/AKT pathway has manifested its compelling influence on multiple cellular process, we further review the roles of hyperactivation of PI3K/AKT pathway in various human cancers. We state the abnormalities of PI3K/AKT pathway in different cancers, which are closely related with tumorigenesis, proliferation, growth, apoptosis, invasion, metastasis, epithelial-mesenchymal transition, stem-like phenotype, immune microenvironment and drug resistance of cancer cells. In addition, we investigated the current clinical trials of inhibitors against PI3K/AKT pathway in cancers and found that the clinical efficacy of these inhibitors as monotherapy has so far been limited despite of the promising preclinical activity, which means combinations of targeted therapy may achieve better efficacies in cancers. In short, we hope to feature PI3K/AKT pathway in cancers to the clinic and bring the new promising to patients for targeted therapies.
引用
收藏
页码:4587 / 4629
页数:43
相关论文